Clinical Pipeline
DA-1726
Obesity is a complex disease in which excessive body fat increases due to nutrient imbalance. Obesity is a medical problem requiring interventional treatment to manage and minimize the risk of other health problems, such as diabetes, high blood pressure, and heart disease, etc.
DA-1726 is a long acting oxyntomodulin peptide analog that can bind and activate both glucagon-like peptide-1 (GLP-1) and glucagon receptors. Activation of GLP-1 and glucagon receptors suppresses appetite and reduces nutrient intake. In addition, activation of glucagon receptors in adipose tissue elicits fat burning. Thus, DA-1726, designed as a well-balanced dual agonist, induces weight loss while effectively improving body composition. Moreover, hypoglycemic effects induced by GLP-1 receptor activation were maintained. DA-1726 has a well understood mechanism of action, and, in pre-clinical mice models, resulted in improved weight loss compared to semaglutide (Wegovy®) and cotadutide (another OXM analogue). Additionally, in pre-clinical mouse models, DA-1726 elicited similar weight reduction, while consuming more food, compared to tirzepatide (Zepbound®) and survodutide (a drug with the same MOA), while also preserving lean body mass and demonstrating improved lipid-lowering effects compared to survodutide. In the Phase 1 multiple ascending dose (MAD) trial in obesity, the 32 mg dose of DA-1726 demonstrated best-in-class potential for weight loss, glucose control, and waist circumference reduction.